Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer

D. S. Ettinger, S. E. Order, M. D. Wharam, M. K. Parker, J. L. Klein, P. K. Leichner

Research output: Contribution to journalArticle

Abstract

A phase I-II study of isotopic immunoglobulin therapy was performed in 18 patients with primary liver cancer; 14 were evaluable for toxicity. The patients received a dose of 37-157 millicuries of 131I-labeled antibody. The dose-limiting factor appears to be hematologic toxicity, especially thrombocytopenia. An objective antitumor effect was seen in six of nine patients who were evaluable for response. Present results suggest that further clinical studies with isotopic immunoglobulin are indicated.

Original languageEnglish (US)
Pages (from-to)289-297
Number of pages9
JournalCancer treatment reports
Volume66
Issue number2
StatePublished - Apr 5 1982

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer'. Together they form a unique fingerprint.

  • Cite this

    Ettinger, D. S., Order, S. E., Wharam, M. D., Parker, M. K., Klein, J. L., & Leichner, P. K. (1982). Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer. Cancer treatment reports, 66(2), 289-297.